Wed.Sep 27, 2023

article thumbnail

September 27, 2023: This Friday’s PCT Grand Rounds to Highlight PROTEUS Consortium

Rethinking Clinical Trials

In this Friday’s PCT Grand Rounds, Claire Snyder of Johns Hopkins University and Norah Crossnohere and Anne Schuster, both of Ohio State University, will present “Navigating the Use of Patient-Reported Outcomes in Research and Practice: The PROTEUS Consortium.” The Grand Rounds session will be held on Friday, September 29, 2023, at 1:00 pm eastern.

147
147
article thumbnail

Mobile health strategies: Should you build or partner for success?

Pharmaceutical Technology

With GlobalData figures showing the value of pharma’s 2023 digital therapeutics-related deals to have grown by 129% since 2018, and the year still not out, it is clear that projects such as companion apps are becoming an increasing priority for life science firms. Here, we debate the benefits of building versus partnering, and share some important considerations for a successful project.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHS Confederation research supports investment in NHS services

Pharma Times

Report shows that if the health service invests in community services hospital admissions will reduce - News - PharmaTimes

81
article thumbnail

Arcturus Therapeutics extends cystic fibrosis treatment deal

Pharmaceutical Technology

Arcturus Therapeutics has extended an existing agreement in place with the Cystic Fibrosis Foundation (CF Foundation) for advancing ARCT-032.

147
147
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Portsmouth NHS Trust maternity team enhances patient experience

Pharma Times

Patient waiting times to receive an appointment have reduced from 6-8 weeks to just 24 hours - News - PharmaTimes

81
article thumbnail

Generics expected to improve access for patients with idiopathic pulmonary fibrosis

Pharmaceutical Technology

The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments approved by the FDA in 2014.

130
130

More Trending

article thumbnail

Alfasigma to buy Intercept Pharmaceuticals for $794m

Pharmaceutical Technology

Alfasigma has signed a definitive agreement for the acquisition of Intercept Pharmaceuticals in an all-cash deal valued at $794m.

130
130
article thumbnail

The epigenetic edge: Harnessing precision medicine’s potential 

Drug Discovery World

HKG Epitherapeutics is a biotechnology company developing novel tools for the early detection of cancer and promoting healthy aging. Founder Dr Moshe Szyf Founder shares the potential of harnessing precision medicine. Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the genetic makeup of individuals with unprecedented accuracy.

59
article thumbnail

UKHSA signs influenza vaccine deal with CSL Seqirus

Pharmaceutical Technology

UKHSA has signed an advance purchase agreement (APA) with healthcare company CSL Seqirus for influenza pandemic vaccines.

130
130
article thumbnail

Women in Science: ScaleReady’s Jenny Stjernberg and her fervent passion for cell and gene therapies

BioPharma Reporter

At Advanced Therapies Europe 2023, BioPharma Reporter caught up with ScaleReady's Jenny Stjernberg to discuss her work at the biotech company, her journey from academia to commercial and female representation in the cell and gene therapies industry.

59
article thumbnail

Running Decentralized Trials at Scale: Planning for Success

There’s been a rapid shift towards decentralization in clinical trials & it’s clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.

article thumbnail

MilliporeSigma opens two new mRNA manufacturing facilities in Germany

Pharmaceutical Technology

MilliporeSigma has opened two new messenger ribonucleic acid (mRNA) drug substance manufacturing facilities in Germany.

130
130
article thumbnail

CAR-T therapy targets over 80% of human tumours

Drug Discovery World

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending dose design aims to rapidly identify the maximum tolerated dose for LEU011.

52
article thumbnail

Interview with Dr. Kristin Yarema, President of Cell Therapy at Poseida Therapeutics – Xtalks Life Science Podcast Ep. 129

XTalks

In this episode, Vera interviews Dr. Kristin Yarema, President of Cell Therapy at Poseida Therapeutics, about Poseida’s cell therapy approach and technologies. Dr. Kristin Yarema, President, Cell Therapy Poseida Therapeutics In April 2023, Dr. Yarema became the President of Cell Therapy at Poseida. She brings a wealth of knowledge from the biopharmaceutical realm, with expertise in oncology and allogeneic T-cell immunotherapy.

52
article thumbnail

UK regulator gives green light to combination for multiple myeloma

Drug Discovery World

The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use on the NHS in England and Wales. The therapy is now recommended within an NHS setting for the treatment of adults with newly diagnosed MM where an autologous stem cell transplant (ASCT) is unsuitable.

52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Protein Bread Brand EQUII Expands Its High-Protein, Low-Carb Offerings

XTalks

EQUII, a food tech startup renowned for its protein bread that focuses on high complete protein and low carbs, is expanding its product line. This new range, which debuted at Expo East last week, includes Plain and Multigrain protein bread, delivering consumers a blend of nutrition without compromising on flavor. The company is also set to launch two more products that will be up for pre-order on its official website.

52
article thumbnail

Drug Channels News Roundup, September 2023: PBM Profits, Specialty Rx Markups, CVS Spending Trends, Pharmacy Pricing Secrets, and Deductibles 101

Drug Channels

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch: A must-read report on hidden sources of PBMs’ profits How generic drugs drive specialty pharmacy profits CVS Health’s unadvertised 2022 drug trend report A shocking look at how PBMs set prescription prices Plus, Dr. Glaucomflecken teaches us about our insurance benefits.

52
article thumbnail

Colorectal Cancer Clinical Trials & Patient Participation: Bridging the Gap

XTalks

Colorectal cancer, the third most frequently diagnosed cancer for both women and men in the US, continues to be a significant area of focus for the medical community. As advancements in research forge ahead, it is imperative to ensure patients are informed about and can access potentially life-saving clinical trials. Enter the Colorectal Cancer Alliance.

52
article thumbnail

Costco builds in telehealth with $29 online visit

pharmaphorum

Costco builds in telehealth with $29 online visit Phil.

64
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Five strategies for delivering digital that makes a difference

pharmaphorum

Five strategies for delivering digital that makes a difference Mike.

59
article thumbnail

NICE turns down Enhertu in “devastating” move, says charity

pharmaphorum

NICE turns down Enhertu in “devastating” move, says charity Phil.

59
article thumbnail

Ionis preps filings for olezarsen in rare disease FCS

pharmaphorum

Ionis preps filings for olezarsen in rare disease FCS Phil.

59
article thumbnail

Ex-Novartis CMO John Tsai pops up at Forcefield

pharmaphorum

Ex-Novartis CMO John Tsai pops up at Forcefield Phil.

59
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

3rd mRNA-Based Therapeutics Summit Europe

pharmaphorum

3rd mRNA-Based Therapeutics Summit Europe Mike.

52
article thumbnail

DTx East: Day 2

pharmaphorum

DTx East: Day 2 Mike.

52